What is EDDA Technology?
EDDA Technology, established in 2003 and headquartered in New Jersey, United States, specializes in providing computer-assisted solutions for the patient care management cycle. The company's core mission revolves around enabling early detection and diagnosis of diseases through advanced technology. This focus positions EDDA Technology at the intersection of medical technology and data analytics, aiming to enhance diagnostic accuracy and efficiency within healthcare systems. The company's commitment to innovation in disease detection underscores its role in advancing medical diagnostics.
How much funding has EDDA Technology raised?
EDDA Technology has raised a total of $150.3M across 2 funding rounds:
Debt
$350K
Other Financing Round
$150M
Debt (2020): $350K with participation from PPP
Other Financing Round (2021): $150M led by OrbiMed, Draper Dragon, 3W Fund, BOCGI, The Morningside Group, The Bridge, SoftBank Group Corp., Matrix Partners China, and Sbcvc
Key Investors in EDDA Technology
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services.
SoftBank Group Corp.
SoftBank Group Corp. is a global technology holding company driving innovation across telecommunications, internet services, artificial intelligence, smart robotics, IoT, and clean energy technologies. Through its diverse portfolio of companies and strategic investments, including leading semiconductor IP providers, SoftBank Group supports the development and scaling of transformative technologies worldwide.
Matrix Partners China
Founded in 1977, Matrix Partners operates as a venture capital firm. The Company invests in software and services, communications equipment, semiconductors, storage, internet, and wireless sectors.
What's next for EDDA Technology?
With the recent infusion of capital, EDDA Technology is poised for significant scaling and further innovation in its diagnostic technologies. The strategic investment suggests a focus on expanding market reach, enhancing its product offerings, and potentially exploring new therapeutic areas or diagnostic capabilities. Future developments are likely to involve leveraging artificial intelligence and machine learning to refine disease detection algorithms and integrate its solutions more deeply into clinical workflows. This capital injection will also support research and development efforts, ensuring EDDA Technology remains at the forefront of medical diagnostic technology and solidifies its position in the competitive healthcare landscape.
See full EDDA Technology company page
